Welcome to our dedicated page for Alkermes Plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes Plc stock.
Alkermes plc (Nasdaq: ALKS) is a global biopharmaceutical company focused on neuroscience, and its news flow reflects both commercial execution and clinical development in this area. Company announcements emphasize proprietary products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, alongside a growing pipeline targeting neurological disorders such as narcolepsy and idiopathic hypersomnia.
Recent news has highlighted alixorexton, Alkermes investigational oral, selective orexin 2 receptor agonist. The company has reported positive phase 2 data from the Vibrance-1 study in narcolepsy type 1 and the Vibrance-2 study in narcolepsy type 2, and has announced that alixorexton is being evaluated in the Vibrance-3 study in idiopathic hypersomnia. In a separate update, Alkermes disclosed that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to alixorexton for narcolepsy type 1, based on phase 1 and phase 2 data.
Investors following ALKS news will also see regular earnings releases, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, and provides updates to its financial expectations. These releases describe trends in proprietary product sales, including VIVITROL, ARISTADA and LYBALVI, and manufacturing and royalty revenues related to VUMERITY and certain long-acting antipsychotic products.
Another key theme in Alkermes news is corporate transactions and financing. The company has announced a transaction agreement, and later an amendment, to acquire Avadel Pharmaceuticals plc, adding LUMRYZ, an FDA-approved once-at-bedtime oxybate for narcolepsy, to its commercial portfolio if the transaction is completed. Related filings describe an amended and restated bridge term loan credit agreement designed to support financing of the proposed acquisition.
Visitors to the ALKS news page can expect updates on clinical trial milestones, regulatory designations, quarterly financial performance, investor conference participation and material corporate agreements. This mix of scientific, financial and strategic information provides context for understanding Alkermes evolving position in neuroscience and sleep medicine.
Alkermes plc (Nasdaq: ALKS) will conduct a conference call on February 16, 2022, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2021 financial results. The call will provide insights into the company's financial expectations for 2022 and include an operational update. Investors can access the webcast and slides via the Investors section on Alkermes' website. Dial-in details for U.S. and international callers are provided. A replay will be available shortly after the event.
Alkermes plc (Nasdaq: ALKS) announced its presentation of clinical data on nemvaleukin alfa, an investigational IL-2 variant immunotherapy, at the ASCO Gastrointestinal Cancers Symposium from Jan. 20-22, 2022. The poster will feature findings from the ARTISTRY-1 phase 1/2 study, evaluating nemvaleukin's efficacy and tolerability alone and with KEYTRUDA in advanced GI cancers. The abstract number is 659, presented by Dr. Ulka N. Vaishampayan. Nemvaleukin aims to enhance tumor-killing immune cells while minimizing immunosuppression.
Summary not available.
Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. EST. CEO Richard Pops will lead the presentation, followed by a Q&A session. The event will be accessible via live webcast on the company's investor relations page and archived for 14 days. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with a portfolio aimed at addiction, schizophrenia, and bipolar I disorder.
Alkermes plc (Nasdaq: ALKS) announced its participation in the fourth annual Evercore ISI HealthCONx Conference on December 2, 2021, at 10:30 a.m. ET. The event will be accessible under the Investors section of Alkermes' website and archived for 14 days. Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience and oncology, with a pipeline targeting neurodegenerative disorders and cancer.
Alkermes plc (Nasdaq: ALKS) has appointed Cato T. Laurencin, M.D., Ph.D., as a new independent director to its Board. Dr. Laurencin is a distinguished academic and pioneer in regenerative engineering with a strong focus on public health and social justice. His appointment, welcomed by CEO Richard Pops, is expected to enhance the company’s innovation and shareholder value creation strategies. Alex Denner of Sarissa Capital views this as a positive outcome for shareholders, anticipating a fresh perspective and improved operational excellence.
Alkermes plc (Nasdaq: ALKS) has initiated a Phase 1 study for ALKS 1140, an investigational HDAC inhibitor aimed at treating neurodegenerative disorders. The study's first subject has been dosed, targeting safety and tolerability in healthy adults. ALKS 1140 is designed to enhance synaptic function, addressing significant unmet medical needs. The trial will involve up to 80 volunteers in Australia and assess pharmacokinetics and pharmacodynamics, marking a crucial step in Alkermes’ clinical program.
Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the Stifel Virtual Healthcare Conference on November 16, 2021, at 9:20 a.m. ET. Investors can access the presentation via the Investors tab on the company's website. Alkermes focuses on developing innovative medicines in neuroscience and oncology, with a range of products targeting addiction, schizophrenia, and bipolar I disorder. The company has R&D facilities in Massachusetts and manufacturing sites in Ireland and Ohio.
On Nov. 8, 2021, Alkermes plc (Nasdaq: ALKS) announced it received notices of partial termination from Janssen Pharmaceutica regarding two license agreements concerning the use of Alkermes' NanoCrystal® technology. This impacts royalties from products like INVEGA SUSTENNA® and INVEGA TRINZA®. While Janssen claims it does not use this technology, Alkermes disputes this and will explore enforcement options. CFO Iain Brown indicated that while cash flow could be adversely impacted in the coming years, the company's long-term outlook remains unchanged, with expected growth from products like LYBALVI®, ARISTADA®, and VUMERITY®.
Alkermes plc (Nasdaq: ALKS) announced it will present a poster on nemvaleukin alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting from Nov. 10-14, 2021. The poster will feature data from the ION-01 study, a phase 2 trial assessing the combination of intravenous nemvaleukin with pembrolizumab in patients with head and neck squamous cell carcinoma. The presentation by Brian Gastman, M.D., is scheduled for Nov. 13, 2021, with the poster available on the SITC platform from Nov. 12, 2021.